Posttraumatic Stress Disorder

14,000,000 Leading Edge Experts on the ideXlab platform

Scan Science and Technology

Contact Leading Edge Experts & Companies

Scan Science and Technology

Contact Leading Edge Experts & Companies

The Experts below are selected from a list of 306 Experts worldwide ranked by ideXlab platform

Chantal De Mey-guillard - One of the best experts on this subject based on the ideXlab platform.

Manuel Gomez - One of the best experts on this subject based on the ideXlab platform.

  • The Posttraumatic Stress Disorder Checklist as a Screening Measure for Posttraumatic Stress Disorder in Rehabilitation After Burn Injuries
    Archives of physical medicine and rehabilitation, 2012
    Co-Authors: Paula J. Gardner, Dafna Knittel-keren, Manuel Gomez
    Abstract:

    Abstract Gardner PJ, Knittel-Keren D, Gomez M. The Posttraumatic Stress Disorder checklist as a screening measure for Posttraumatic Stress Disorder in rehabilitation after burn injuries. Objectives To determine the profile of Posttraumatic Stress Disorder (PTSD) among outpatients with burn injuries referred to psychology in a rehabilitation hospital, and the utility of the Posttraumatic Stress Disorder Checklist-Civilian Version (PCL-C) as a screening measure for PTSD. Design Retrospective psychological chart review. Setting Outpatient burn clinic of a rehabilitation hospital. Participants Outpatients (N=132) with burns referred to psychology between December 1999 and January 2010. Interventions Psychological evaluation and self-report questionnaires measuring PTSD and depression. Main Outcome Measures The Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition to assess clinical diagnosis of Disorders, PCL-C to measure PTSD, and the Beck Depression Inventory-II to measure depression. Results Of 132 outpatients, 127 (96%) had work-related injuries, 116 (88%) were men, and 16 (12%) were women. Mean age ± SD at injury was 39.0±11.1 years. Mean time from injury to assessment was 15.7±42.7 months. Burn etiology included: electrical (46.2%), scald (28.0%), flame (16.7%), chemical (5.3%), and contact (3.8%). Most patients (75%) were diagnosed with PTSD, either clinical (39.4%) or subclinical (35.6%). PTSD (clinical or subclinical) was frequently diagnosed in the following etiology groups: scald (85.7%), flame (77.3%), and electrical (74.6%). There were significant relationships between PTSD and depression ( P P Conclusions There was a high prevalence of PTSD (clinical or subclinical) among outpatients with burns referred to psychology. Prospective screening of psychological symptoms, clinical assessment, and intervention is warranted, especially for patients with work-related burn injuries. Our results suggest that PCL-C is a useful screening measure for PTSD in patients with burns.

Jonathan R. T. Davidson - One of the best experts on this subject based on the ideXlab platform.

  • treatment of Posttraumatic Stress Disorder with venlafaxine extended release a 6 month randomized controlled trial
    Archives of General Psychiatry, 2006
    Co-Authors: Jonathan R. T. Davidson, David S Baldwin, Dan J Stein, Enrique Kuper, I Benattia, Saeed Ahmed, Ron Pedersen, Jeff Musgnung
    Abstract:

    Context No large-scale Posttraumatic Stress Disorder drug trials have been conducted to evaluate treatment effects beyond 12 weeks outside of those with selective serotonin reuptake inhibitors. Objective To evaluate the efficacy of venlafaxine extended release (ER), a serotonin norepinephrine reuptake inhibitor, in Posttraumatic Stress Disorder. Design 6-month, double-blind, placebo-controlled trial. Setting International study at 56 sites. Patients Adult outpatients (N = 329) with a primary diagnosis of Posttraumatic Stress Disorder as defined in the DSM-IV , symptoms for 6 months or longer, and a 17-item Clinician-Administered Posttraumatic Stress Disorder Scale score of 60 or higher. Intervention Patients randomly assigned to receive flexible doses of venlafaxine ER (37.5-300 mg/d) or placebo for 24 weeks. Main Outcome Measures Primary measure was the change from baseline in the Clinician-Administered Posttraumatic Stress Disorder Scale score. Secondary measures included remission, defined as a Clinician-Administered Posttraumatic Stress Disorder Scale score of 20 or lower, and changes in symptom cluster scores, frequency of remission, and time to remission. Measures of Stress vulnerability, resilience, depression, quality of life, functioning, and global illness severity were also taken. Results Mean changes from baseline in Clinician-Administered Posttraumatic Stress Disorder Scale total scores at end point were −51.7 for venlafaxine ER and −43.9 for placebo ( P  = .006). Improvement was significantly greater for the venlafaxine ER group than for the placebo group in cluster scores for reexperiencing ( P  = .008) and avoidance/numbing ( P  = .006), but not for hyperarousal. Remission rates were 50.9% for venlafaxine ER and 37.5% for placebo ( P  = .01). The venlafaxine ER group also showed significantly greater improvement at end point than the placebo group ( P Conclusion In this study, venlafaxine ER was effective and well tolerated in short-term and continuation treatment of patients with Posttraumatic Stress Disorder.

  • mirtazapine vs placebo in Posttraumatic Stress Disorder a pilot trial
    Biological Psychiatry, 2003
    Co-Authors: Jonathan R. T. Davidson, Richard H Weisler, Marian I Butterfield, Charles D Casat, Kathryn M Connor, Stewart D Barnett, Susan Van Meter
    Abstract:

    Abstract Background Based on an earlier pilot study, as well as a theoretical consideration of its mechanism of action, we undertook a placebo-controlled, double-blind trial of mirtazapine in Posttraumatic Stress Disorder. Methods Twenty-nine patients were randomized to receive drug up to 45 mg/day or placebo double-blind on a 2:1 ratio for 8 weeks, with data being available for analysis in 26. Primary outcome measures comprised the Short Posttraumatic Stress Disorder Rating Interview (SPRINT) Global Improvement item and total score. Secondary measures comprised the Davidson Trauma Scale, Structured Interview for Posttraumatic Stress Disorder and Hospital Anxiety Depression Scale. Adverse events were also measured. Results On the Short Posttraumatic Stress Disorder Rating Interview Global Improvement measure, rates of response were 64.7% and 20.0% for mirtazapine and placebo. Treatment effects in favor of mirtazapine were noted on the Short Posttraumatic Stress Disorder Rating Interview global, Structured Interview for Posttraumatic Stress Disorder, and Hospital Anxiety Depression Scale anxiety subscale scores. The drug was well tolerated. Conclusions Mirtazapine was more effective than placebo on some measures in Posttraumatic Stress Disorder and general anxiety symptoms.

Susan Van Meter - One of the best experts on this subject based on the ideXlab platform.

  • mirtazapine vs placebo in Posttraumatic Stress Disorder a pilot trial
    Biological Psychiatry, 2003
    Co-Authors: Jonathan R. T. Davidson, Richard H Weisler, Marian I Butterfield, Charles D Casat, Kathryn M Connor, Stewart D Barnett, Susan Van Meter
    Abstract:

    Abstract Background Based on an earlier pilot study, as well as a theoretical consideration of its mechanism of action, we undertook a placebo-controlled, double-blind trial of mirtazapine in Posttraumatic Stress Disorder. Methods Twenty-nine patients were randomized to receive drug up to 45 mg/day or placebo double-blind on a 2:1 ratio for 8 weeks, with data being available for analysis in 26. Primary outcome measures comprised the Short Posttraumatic Stress Disorder Rating Interview (SPRINT) Global Improvement item and total score. Secondary measures comprised the Davidson Trauma Scale, Structured Interview for Posttraumatic Stress Disorder and Hospital Anxiety Depression Scale. Adverse events were also measured. Results On the Short Posttraumatic Stress Disorder Rating Interview Global Improvement measure, rates of response were 64.7% and 20.0% for mirtazapine and placebo. Treatment effects in favor of mirtazapine were noted on the Short Posttraumatic Stress Disorder Rating Interview global, Structured Interview for Posttraumatic Stress Disorder, and Hospital Anxiety Depression Scale anxiety subscale scores. The drug was well tolerated. Conclusions Mirtazapine was more effective than placebo on some measures in Posttraumatic Stress Disorder and general anxiety symptoms.

Valérie A.g. Ventureyra - One of the best experts on this subject based on the ideXlab platform.

Related terms

Posttraumatic Stress Disorder - 15 days free trial to Access Experts & Abstracts